Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy
XTalks
JUNE 28, 2023
million price tag of Elevidys, a one-time gene therapy. The progression of DMD is often rapid, and those affected usually face a significantly shortened lifespan with severe physical limitations. Options for managing the symptoms of DMD have been limited. In a media call, Sarepta CEO Douglas Ingram revealed the $3.2
Let's personalize your content